Clinical Trials Logo

Early Psychosis clinical trials

View clinical trials related to Early Psychosis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06032182 Recruiting - Early Psychosis Clinical Trials

PSYCHE Cognitive Remediation & Social Recovery Study

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

This study is a pilot feasibility study embedded in the Early Intervention in Psychosis (EIP) services in Ireland. It explores the feasibility and acceptability of a combined cognitive remediation training and social recovery therapy intervention.

NCT ID: NCT04411225 Recruiting - Early Psychosis Clinical Trials

Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis

Start date: June 1, 2022
Phase: Phase 3
Study type: Interventional

This is an outpatient, single center, between-group, double blind, placebo controlled design. Approximately 120 adolescents and adult patients will be randomized to either have their treatment augmented with Cannabidiol Oral Solution (CBD) or with a matching CBD placebo for 8 weeks. The study will examine CBD as an augmentation strategy in early psychosis. It is hypothesized that CBD will improve symptoms, neurocognition, markers of inflammation and eating behaviors. Importantly, moderators and mediators of the CBD effects will be explored.

NCT ID: NCT04317807 Recruiting - Early Psychosis Clinical Trials

R33: Levetiracetam in Early Psychosis

Start date: August 27, 2020
Phase: Phase 2
Study type: Interventional

This is a 12-week study of levetiracetam added to a second generation antipsychotic in early psychosis patients who have been ill for less than 5 years and continue to experience psychotic symptoms despite at least 8 weeks of antipsychotic treatment. Levetiracetam (Keppra) is a medication approved for the treatment of epilepsy; it reduces excessive activity in the brain. This study will test the hypotheses that adding levetiracetam will improve psychotic symptoms that are unresponsive to antipsychotic treatment and will protect the brain from atrophy (volume loss). .